Sequent Scientific Limited — Important, 22-11-2024: General Updates

Sequent Scientific Limited has executed strategic acquisitions to enhance its ownership in its subsidiaries. The company has consolidated its shareholding in N-VET AB, Sweden, acquiring an additional 3.90% stake for SEK 344,000, resulting in N-VET AB becoming a wholly-owned subsidiary. N-VET AB, engaged in animal healthcare trading, reported sales of approximately SEK 21.27 million for FY 2023-24.

In a parallel move, Sequent has also acquired a 5% stake in Alivira Italia SRL, Italy, for €15,000. This acquisition solidifies Alivira Italia's status as a wholly-owned subsidiary and contributes to Sequent's strategic focus on the animal healthcare sector. Alivira Italia, with FY 2023-24 sales of about €1.57 million, similarly operates within the pharmaceuticals industry.

These acquisitions are expected to bolster Sequent's market position and operational efficiency in the animal healthcare segment, presenting a positive outlook for growth and expansion in the sector. Investors should monitor the integration of these subsidiaries and the potential for increased market share.